title: Bioavailability of tyrosine kinase inhibitors: an added component of assessment.
abstract: The growing prominence of tyrosine kinase inhibitors (TKIs) as treatment for malignancies prompts oncology nurses to expand the scope of their patient assessment. Because TKIs as oral agents have a different bioavailability than parenteral agents, factors that alter drug absorption and metabolism can have a measurable effect on the amount of active, available drug when TKIs are prescribed. In relation to TKIs as cancer therapies and intended dosing, this article reviews three drug absorption and metabolism factors: changes in stomach pH, as well as P-glycoprotein and cytochrome P450 interactions.
authors.affiliation: Oncology Clinical Trials Research Team at Kaiser Permanente, Roseville, CA.
authors.forename: Kristine Deano
authors.initials: KD
authors.lastname: Abueg
mesh_terms: D001682:Biological Availability; D047428:Protein Kinase Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: drug interactions; targeted therapies; tyrosine kinase inhibitors